These findings suggested that pediatric ALL patients with CDKN2A/B deletion were more likely to exhibit BCR-ABL1 positivity in conjunction with IKZF1 deletion, and all patients were BCR-ABL1 (p190 type) positivity combined with IKZF1 deletion (IK16 type) positive (These data are summarized in Table 4). This evidence concerns the gene IKZF1 and acute lymphoblastic leukemia.